Sight SciencesSGHT +0.18%72 9-Day RSI is 56.98 as of Jul. 03, 2026. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.50 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 870 Medical Devices & Instruments companies, Sight Sciences ranks worse than 70.8% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-03), Sight Sciences's 9-Day RSI is 56.98.
The industry rank for Sight Sciences's 9-Day RSI or its related term are showing as below:
SGHT's 9-Day RSI is ranked worse than 70.8% of 870
companies
in the Medical Devices & Instruments industry
Industry Median: 49.14
vs SGHT: 56.98
Sight Sciences (NAS:SGHT) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Sight Sciences 9-Day RSI Related Terms
SGHT vs SENS, LAB, TMCI: 9-Day RSI Comparison
For the Medical Devices subindustry, Sight Sciences's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Sight Sciences's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (SGHT) has a 9-Day RSI of 56.98 as of Jul. 03, 2026. According to the industry distribution chart, Sight Sciences ranks #616 out of 870 companies in the Medical Devices & Instruments industry, placing it in the top 70.8%.
Is Sight Sciences' 9-Day RSI too high?
Sight Sciences' current 9-Day RSI is 56.98. The Medical Devices & Instruments industry median 9-Day RSI is 49.14. Sight Sciences' value of 56.98 is 16% above this industry median. Based on the distribution chart, Sight Sciences ranks #616 out of 870 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' 9-Day RSI compare to SENS and LAB?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #616 out of 870 companies for 9-Day RSI. This places Sight Sciences in the lower half of its industry. The industry median 9-Day RSI is 49.14. Sight Sciences' value of 56.98 is 16% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 49.14, based on 870 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sight Sciences's current 9-Day RSI of 56.98 is 16% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 49.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current 9-Day RSI is 56.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.50, compared to a current price of $5.44 — trading 20.9% above its estimated fair value. The current 9-Day RSI is 56.98 and 16% above the Medical Devices & Instruments industry median of 49.14. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Sight Sciences (SGHT), the current 9-Day RSI is 56.98 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $5.44 is trading 20.9% above its estimated GF Value™ of $4.50.
GuruFocus considers Sight Sciences to be Modestly Overvalued.
Key valuation signals for SGHT:
9-Day RSI: 56.98
GF Value™: $4.50 vs. price of $5.44 (20.9% above fair value)
Industry Position: 16% above the Medical Devices & Instruments median (#616 of 870)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score
Get the complete analysis for SGHT
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 